Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family.
The spread of carbapenem-resistant members of the Enterobacteriaceae family (CRE) harboring carbapenemases is an emerging public health threat. As KPC-producing Klebsiella species are endemic in our tertiary care hospital, we aimed to evaluate a PCR-based surveillance test for identification of rectal carriage of KPC-producing CRE. We conducted a surveillance study between May and December 2007. Rectal swabs were collected from patients known to harbor CRE and from contacts of newly discovered patients harboring CRE. Specimens were evaluated by culture and by PCR analysis for blaKPC and were defined as positive if CRE was cultured and blaKPC was identified. Discrepant results between the culture and PCR analysis were resolved by subculturing, repeating the PCR, and performing a hydrolysis assay. Positive CRE cultures prior or subsequent to the time of sampling for the study were also taken into consideration. Sensitivity, specificity, and time to result were calculated. A total of 755 swabs were included. Concordant results were documented for 735 specimens; 51 were positive as determined by both PCR and culture. Discrepancies existed for 20 swabs; 9 were blaKPC negative and CRE culture positive, and 11 were blaKPC positive and CRE culture negative. After repeat testing, a total of 64 samples were classified as blaKPC-positive CRE. The sensitivity and specificity of the PCR analysis were 92.2% and 99.6%, respectively, and those of the culture were 87.5% and 99.4%, respectively. Over the last 3 months of the study, the sensitivity of the PCR improved to 96.3%, versus 77.8% for culture. Time to result was 30 h for the PCR and 60 h (negative) and 75 h (positive) for the CRE culture. blaKPC PCR-based testing is a useful method for the surveillance of KPC-producing CRE. Its main advantage over culturing is a shorter time to result, and it may prove to be more sensitive.
Schechner
Vered
V
Division of Epidemiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Straus-Robinson
Keren
K
Schwartz
David
D
Pfeffer
Iris
I
Tarabeia
Jalal
J
Moskovich
Rina
R
Chmelnitsky
Inna
I
Schwaber
Mitchell J
MJ
Carmeli
Yehuda
Y
Navon-Venezia
Shiri
S
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000201:enzymology* / Q000235:genetics; D005243:Feces / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D016133:Polymerase Chain Reaction / Q000379:methods*; D012680:Sensitivity and Specificity; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000235:genetics*
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D001618:beta-Lactamases
Antimicrob Agents Chemother. 2006 Oct;50(10):3396-406
17005822
Antimicrob Agents Chemother. 1997 Mar;41(3):563-9
9055993
Clin Infect Dis. 2002 Oct 1;35(7):834-41
12228820
Clin Infect Dis. 2004 Jul 1;39(1):55-60
15206053
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents
17630334
JAMA. 2008 Dec 24;300(24):2911-3
19109119
J Clin Microbiol. 2005 Nov;43(11):5639-41
16272497
Antimicrob Agents Chemother. 2008 Mar;52(3):1028-33
18086836
N Engl J Med. 2001 May 10;344(19):1427-33
11346807
Antimicrob Agents Chemother. 2004 Dec;48(12):4793-9
15561858
Int J Antimicrob Agents. 2007 Dec;30(6):525-9
17931835
Antimicrob Agents Chemother. 2007 Aug;51(8):3026-9
17562800
Emerg Infect Dis. 2006 Aug;12(8):1209-13
16965699
J Clin Microbiol. 2008 Sep;46(9):2879-83
18614657
Antimicrob Agents Chemother. 2009 Feb;53(2):818-20
19029323
Clin Microbiol Infect. 2001 Feb;7(2):88-91
11298149
Antimicrob Agents Chemother. 2008 Apr;52(4):1413-8
18227191
Eur J Clin Microbiol Infect Dis. 2009 Mar;28(3):309-11
18719955
J Clin Microbiol. 2007 Aug;45(8):2723-5
17581941
Clin Infect Dis. 1999 Dec;29(6):1411-8
10585788
Crit Care. 2006 Feb;10(1):R25
16469125
Antimicrob Agents Chemother. 2006 Sep;50(9):3098-101
16940107
J Hosp Infect. 2007 Jan;65(1):24-8
17145100